GlaxoSmithKline to finalize $15 billion bid for Pfizer OTC unit

Share this article:
UK drugmaker GlaxoSmithKline is finalizing a $15 billion bid for Pfizer’s over-the-counter drugs business, according to reports in the Financial Times (FT), The Times (of London) and others. The Financial Times reported that Glaxo would bid at least $14 billion for the unit and would not go higher than $16 billion. The Times report indicated Glaxo would spend up to $15 billion. If Glaxo’s bid is successful, it would make the company the world’s largest manufacturer of non-prescription drugs. Other companies interested in the division include Colgate Palmolive, Bayer and Johnson & Johnson. Pfizer said early this year that it would consider selling or spinning off its consumer-products unit, which markets brands including Listerine, Sudafed and Lubriderm. The division’s sales rose 10 % to $3.8 billion last year as sales of Pfizer’s prescription products fell 4% to $44 billion.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.